Lineage Cell Therapeutics LCTX
NYSE LCTX
$0.95 -0.02 (-1.69%)
As of: Sep 29, 2026 · 3:59 PM EDT

Lineage Cell Therapeutics (LCTX) Operating Margin (2010 - 2026)

Updated

Lineage Cell Therapeutics (LCTX) posted Operating Margin of -834.71% for Q2 2026, down 119.33 percentage points from -715.37% a year earlier and down 394.53 percentage points from the prior quarter.

Analysis

Lineage Cell Therapeutics (LCTX) Operating Margin (2010 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Operating Margin at Lineage Cell Therapeutics was -205.23%, up 117.61 percentage points year-over-year; for FY2025, it came in at -251.57%, down 25.47 percentage points from FY2024.

  • Annual Operating Margin shows a five-year change of +1196.78 percentage points (FY2020 to FY2025).
  • In prior years, Lineage Cell Therapeutics' Operating Margin was -226.11% in FY2024 (+50.39 pp), -276.50% in FY2023 (-123.33 pp), -153.17% in FY2022 (+980.47 pp) and -1133.63% in FY2021 (+314.72 pp).
  • The Q2 2026 figure stands as the lowest quarterly Operating Margin since Q4 2021.
  • On a year-over-year basis, Operating Margin increased in four of the last eight quarters, with an average year-over-year change of +30.50 percentage points.
  • The strongest year-over-year quarter for Operating Margin in the past five years was Q4 2022, with a gain of 2070.95 percentage points; the weakest was Q4 2021, with a drop of 760.74 percentage points.
  • According to Business Quant data, Operating Margin for the three prior quarters was -440.17% (Q1 2026), -99.09% (Q4 2025) and -102.85% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 28.21%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 37.86%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -3.52%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 32.97%
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 20.57%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 34.95%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -133.21%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 28.37%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 37.40%
10 Lineage Cell Therapeutics 245.32 Mn 43.73 Mn - -834.71%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -834.71%
Mar 31, 2026 -440.17%
Dec 31, 2025 -99.09%
Sep 30, 2025 -102.85%
Jun 30, 2025 -715.37%
Mar 31, 2025 -433.09%
Dec 31, 2024 -178.17%
Sep 30, 2024 -101.61%
Jun 30, 2024 -416.69%
Mar 31, 2024 -461.29%
Dec 31, 2023 -304.69%
Sep 30, 2023 -538.12%
Jun 30, 2023 -155.78%
Mar 31, 2023 -278.37%
Dec 31, 2022 -346.68%
Sep 30, 2022 -175.15%
Jun 30, 2022 -92.99%
Mar 31, 2022 -122.13%
Dec 31, 2021 -2,417.64%
Sep 30, 2021 -301.45%
API Access

Lineage Cell Therapeutics Operating Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-margin&ticker=LCTX&period=max&api_key=YOUR_API_KEY